FDA Approves Vizz Eye Drops for Instant Near Vision Improvement

The FDA has approved Vizz, a once-daily eye drop that improves near vision without reading glasses. Created by Lenz Therapeutics, Vizz uses aceclidine to temporarily reduce pupil size and sharpen close-up focus. The drop works by creating a "pinhole effect" that extends the eye's depth of focus, with noticeable improvement in vision within 30 minutes and lasting up to 10 hours. Strong clinical results and minimal side effects have led to its approval. Vizz could be a game changer for the estimated 128 million Americans living with presbyopia.

The U.S. Food and Drug Administration (FDA) has approved VIZZ, a once-daily eye drop developed by Lenz Therapeutics, for the treatment of presbyopia. This condition, which affects approximately 128 million adults in the United States, causes age-related near vision loss and typically requires correction with glasses or contact lenses [1].

VIZZ operates by using the active ingredient aceclidine to temporarily reduce pupil size, creating a "pinhole effect" that extends the eye's depth of focus. This mechanism improves near vision within 30 minutes and maintains the effect for up to 10 hours. The drop does not significantly stimulate the eye's focusing muscles, avoiding the "zoomed-in" effect or myopic shift that can occur with older treatments [2].

The FDA approval is based on the results of three randomized, double-masked, controlled Phase 3 studies, involving a total of 683 participants. These studies demonstrated the efficacy and safety of VIZZ, with no serious adverse events observed over more than 30,000 treatment days. Common mild side effects included installation site irritation, dim vision, and headaches [3].

LENZ Therapeutics expects to make VIZZ commercially available by mid-Q4 2025, with samples becoming available as early as October 2025. This strategic timing allows the company to prepare for a successful commercial rollout and capitalize on the first-mover advantage in this therapeutic space [1].

VIZZ represents a significant advancement in the treatment of presbyopia, offering a convenient, effective, and well-tolerated solution for millions of Americans struggling with age-related near vision loss.

References:
[1] https://newatlas.com/aging/age-related-near-sighted-drops-vizz/
[2] https://glance.eyesoneyecare.com/press-releases/lenz-therapeutics-announces-fda-approval-of-vizz-aceclidine-ophthalmic-solution-1-44-for-the-treatment-of-presbyopia/
[3] https://www.gurufocus.com/news/3023799/lenz-therapeutics-announces-us-fda-approval-of-vizz-for-the-treatment-of-presbyopia-lenz-stock-news